{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:56:03Z","timestamp":1789764963157,"version":"4.0.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Individuals with chronic lymphocytic leukemia (CLL) face an increased risk for severe COVID-19. This study from Sweden, a country that only had a few mandatory restrictions at the onset of the pandemic, used 10 nationwide registers to compare the risks for severe COVID-19 outcomes of polymerase chain reaction\u2013verified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections through February 2023 in individuals with and those without CLL. From a population of 8 275 839 (6653 CLL) individuals born between 1930 and 2003, 2 088 163 first infections (1289 CLL) were included. The 90-day all-cause mortality rate and adjusted relative risk (aRR; 95% confidence interval) for individuals with CLL vs the general population was 24.8% (1.95; 1.58-2.41) during wild-type, 17.2% (2.38; 1.58-3.57) during Alpha, 4.1% (0.71; 0.24-2.08) during Delta, and 12.6% (1.49; 1.24-1.78) during Omicron infections. Their mortality during Omicron was 0.6% (&amp;lt;65 years), 5.4% (65-74 years), and 19.7% (\u226575 years). Small molecule inhibitors (1.56; 1.03-2.37) and corticosteroid usage (1.45; 1.04-2.02) was associated with increased mortality. Next, we analyzed the all-cause mortality in the capital (Stockholm), widely affected by SARS-CoV-2 at the onset of the pandemic. Mortality in individuals with CLL increased by 55% during the first 6 months of 2020 vs 2019, and the age- and sex-aRR by 30 June was 1.53 (1.09-2.15) for individuals with CLL (P = .02) and 1.29 (1.25-1.33) for the general population (P &amp;lt; .001). Collectively, a significantly increased risk for severe COVID-19 and death was observed among individuals with CLL in Sweden, particularly at the onset of the pandemic when few national protective measures were introduced and also after Omicron emerged, emphasizing the need for a more pro-active pandemic strategy for CLL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015260","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:01:36Z","timestamp":1740171696000},"page":"3170-3181","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-098X","authenticated-orcid":false,"given":"Pontus","family":"Hedberg","sequence":"first","affiliation":[{"name":"1Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Blixt","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"3Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Eketorp Sylvan","sequence":"additional","affiliation":[{"name":"3Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-2902","authenticated-orcid":false,"given":"Isabela","family":"Killander M\u00f6ller","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-9426","authenticated-orcid":false,"given":"Hannes","family":"Lindahl","sequence":"additional","affiliation":[{"name":"4Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden"},{"name":"5Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-6350","authenticated-orcid":false,"given":"Fredrik","family":"Kahn","sequence":"additional","affiliation":[{"name":"6Department of Clinical Sciences, Lund, Section for Infection Medicine, Lund University, Lund, Sweden"},{"name":"7Department of Infectious Diseases, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5719-5601","authenticated-orcid":false,"given":"\u00c5sa","family":"Nilsdotter-Augustinsson","sequence":"additional","affiliation":[{"name":"8Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-8587","authenticated-orcid":false,"given":"Mats","family":"Fredrikson","sequence":"additional","affiliation":[{"name":"9Department of Biomedical and Clinical Sciences, Faculty of Medicine, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Nystr\u00f6m","sequence":"additional","affiliation":[{"name":"9Department of Biomedical and Clinical Sciences, Faculty of Medicine, Link\u00f6ping University, Link\u00f6ping, Sweden"},{"name":"10Department of Clinical Immunology and Transfusion Medicine, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-3713","authenticated-orcid":false,"given":"Peter","family":"Bergman","sequence":"additional","affiliation":[{"name":"4Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden"},{"name":"11Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-5964","authenticated-orcid":false,"given":"Christina","family":"Carlander","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"},{"name":"12Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden"},{"name":"13Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-4870","authenticated-orcid":false,"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[{"name":"1Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"},{"name":"12Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Naucl\u00e9r","sequence":"additional","affiliation":[{"name":"12Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden"},{"name":"14Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"3Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-5737","authenticated-orcid":false,"given":"Lotta","family":"Hansson","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"3Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2025062511215997000_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br Med Bull"},{"issue":"7","key":"2025062511215997000_bib2","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2017.182006","article-title":"Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"103","author":"Andersen","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"2025062511215997000_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41375-020-0884-z","article-title":"Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)","volume":"35","author":"Mauro","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2025062511215997000_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.26388","article-title":"Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis","volume":"97","author":"Muchtar","year":"2022","journal-title":"Am J Hematol"},{"issue":"25","key":"2025062511215997000_bib5","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood.2022017814","article-title":"Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion","volume":"140","author":"Shen","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025062511215997000_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.14740\/jh1140","article-title":"Local and systemic immunity during five vaccinations against SARS-CoV-2 in zanubrutinib-treated patients with chronic lymphocytic leukemia","volume":"12","author":"Andersson","year":"2023","journal-title":"J Hematol"},{"issue":"8","key":"2025062511215997000_bib7","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1002\/ajh.25851","article-title":"Management of CLL patients early in the COVID -19 pandemic: an international survey of CLL experts","volume":"95","author":"Koffman","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"2025062511215997000_bib8","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"2025062511215997000_bib9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2025062511215997000_bib10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41375-021-01424-w","article-title":"Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients","volume":"36","author":"Blixt","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2025062511215997000_bib11","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/apa.15582","article-title":"The first eight months of Sweden\u2019s COVID-19 strategy and the key actions and actors that were involved","volume":"109","author":"Ludvigsson","year":"2020","journal-title":"Acta Paediatr"},{"issue":"1","key":"2025062511215997000_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/apa.16535","article-title":"How Sweden approached the COVID -19 pandemic: summary and commentary on the National Commission Inquiry","volume":"112","author":"Ludvigsson","year":"2023","journal-title":"Acta Paediatr"},{"key":"2025062511215997000_bib13","doi-asserted-by":"crossref","first-page":"1206732","DOI":"10.3389\/fpubh.2023.1206732","article-title":"The Swedish COVID-19 approach: a scientific dialogue on mitigation policies","volume":"11","author":"Bj\u00f6rkman","year":"2023","journal-title":"Front Public Health"},{"issue":"5","key":"2025062511215997000_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025062511215997000_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.19087","article-title":"Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL","volume":"204","author":"Shen","year":"2024","journal-title":"Br J Haematol"},{"key":"2025062511215997000_bib16","doi-asserted-by":"crossref","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"eBioMedicine"},{"issue":"1","key":"2025062511215997000_bib17","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1097\/HS9.0000000000000811","article-title":"COVID-19 vaccination response and its practical application in patients with chronic lymphocytic leukemia","volume":"7","author":"Shadman","year":"2023","journal-title":"HemaSphere"},{"issue":"12","key":"2025062511215997000_bib18","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1007\/s00277-024-05869-8","article-title":"Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia","volume":"103","author":"Kontandreopoulou","year":"2024","journal-title":"Ann Hematol"},{"issue":"2","key":"2025062511215997000_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/23744235.2024.2405582","article-title":"Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden","volume":"57","author":"M\u00f6ller","year":"2025","journal-title":"Infect Dis (Lond)"},{"issue":"2","key":"2025062511215997000_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaci.2024.10.013","article-title":"Inborn errors of immunity are associated with increased COVID-19-related hospitalization and intensive care compared to the general population","volume":"155","author":"Lindahl","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2025062511215997000_bib21","unstructured":"Regional Cancer Center, Sweden\n          . National Quality Registry Chronic Lymphocytic Leukemia. Updated 26 September 2024. Accessed 25 October 2024. https:\/\/cancercentrum.se\/samverkan\/cancerdiagnoser\/blod-lymfom-myelom\/kronisk-lymfatisk-leukemi-kll\/kvalitetsregister\/."},{"issue":"1","key":"2025062511215997000_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/eurpub\/ckad209","article-title":"Sociodemographic characteristics and COVID-19 testing rates: spatiotemporal patterns and impact of test accessibility in Sweden","volume":"34","author":"Kennedy","year":"2024","journal-title":"Eur J Public Health"},{"issue":"1","key":"2025062511215997000_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/infdis\/jiad382","article-title":"Post\u2013COVID-19 condition after SARS-CoV-2 infections during the Omicron surge vs the Delta, Alpha, and wild type periods in Stockholm, Sweden","volume":"229","author":"Hedberg","year":"2024","journal-title":"J Infect Dis"},{"key":"2025062511215997000_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.02.012","article-title":"Cox regression using a calendar time scale was unbiased in simulations of COVID-19 vaccine effectiveness & safety","volume":"156","author":"Lund","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2025062511215997000_bib25","doi-asserted-by":"crossref","first-page":"e1077","DOI":"10.1002\/jha2.1077","article-title":"Uptake of the first to fifth doses of coronavirus disease 2019 vaccine in individuals with chronic lymphocytic leukaemia: a nationwide cohort study in Sweden","volume":"6","author":"Hedberg","year":"2025","journal-title":"eJHaem"},{"issue":"1","key":"2025062511215997000_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13054-023-04349-1","article-title":"Limitation of life-sustaining therapies in critically ill patients with COVID-19: a descriptive epidemiological investigation from the COVID-ICU study","volume":"27","author":"Giabicani","year":"2023","journal-title":"Crit Care"},{"key":"2025062511215997000_bib27","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-025-07790-8","article-title":"Association of hospital and intensive care unit occupancy and non-admission to the intensive care unit decisions: a retrospective cohort study [published correction appears in Intensive Care Med 2025]","author":"Sotoodeh","year":"17  2025","journal-title":"Intensive Care Med"},{"key":"2025062511215997000_bib28","doi-asserted-by":"crossref","first-page":"1396913","DOI":"10.3389\/fonc.2024.1396913","article-title":"The impact of Bruton\u2019s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia","volume":"14","author":"Yang","year":"2024","journal-title":"Front Oncol"},{"issue":"12","key":"2025062511215997000_bib29","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1007\/s00277-024-05744-6","article-title":"Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG)","volume":"103","author":"Zhu","year":"2024","journal-title":"Ann Hematol"},{"issue":"12","key":"2025062511215997000_bib30","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2025062511215997000_bib31","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1080\/10428194.2022.2053532","article-title":"How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia","volume":"63","author":"Deodato","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2025062511215997000_bib32","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s00277-024-05738-4","article-title":"COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study","volume":"103","author":"Thau","year":"2024","journal-title":"Ann Hematol"},{"issue":"11","key":"2025062511215997000_bib33","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.cmi.2022.05.014","article-title":"The association between pre-exposure to glucocorticoids and other immunosuppressant drugs with severe COVID-19 outcomes","volume":"28","author":"Brodin","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2025062511215997000_bib34","doi-asserted-by":"crossref","first-page":"e080640","DOI":"10.1136\/bmjopen-2023-080640","article-title":"Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19: analysis of a population-based cohort","volume":"14","author":"Einarsdottir","year":"2024","journal-title":"BMJ Open"},{"issue":"4","key":"2025062511215997000_bib35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/eurpub\/ckae091","article-title":"Excess mortality in Denmark, Finland, Norway and Sweden during the COVID-19 pandemic 2020-2022","volume":"34","author":"Forthun","year":"2024","journal-title":"Eur J Public Health"},{"key":"2025062511215997000_bib36","unstructured":"Regeringskansliet\n          . Sweden during the pandemic. 2022. Accessed 27 September 2022. https:\/\/regeringen.se\/rattsliga-dokument\/statens-offentliga-utredningar\/2022\/02\/sou-202210\/."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3170\/2381616\/blooda_adv-2024-015260-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3170\/2381616\/blooda_adv-2024-015260-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:22:07Z","timestamp":1750864927000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/13\/3170\/535659\/Outcomes-of-the-COVID-19-pandemic-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015260","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,8]]},"published":{"date-parts":[[2025,7,8]]}}}